| Literature DB >> 19562087 |
Abstract
Cannabinoids have been shown to possess anticonvulsant properties in whole animal models of epilepsy. The present investigation sought to examine the effects of cannabinoid receptor activation on kainic acid (KA)-induced epileptiform neuronal excitability. Under urethane anesthesia, acute KA treatment (10 mg kg(-1), i.p.) entrained the spiking mode of simultaneously recorded neurons from random firing to synchronous bursting (% change in burst rate). Injection of the high-affinity cannabinoid agonist (-)-11-hydroxy-8-tetrahydrocannabinol-dimethyl-heptyl (HU210, 100 mug kg(-1), i.p.) following KA markedly reduced the burst frequency (% decrease in burst frequency) and reversed synchronized firing patterns back to baseline levels. Pre-treatment with the central cannabinoid receptor (CB1) antagonist N-piperidino-5-(4-clorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-3-pyrazole-carboxamide (rimonabant, SR141716A 3 mg kg(-1), i.p.) completely prevented the actions of HU210. The present results indicate that cannabinoids exert their antiepileptic effects by impeding pathological synchronization of neuronal networks in the hippocampus.Entities:
Keywords: CB1 receptor; GABA; multiple single-neuron recording; urethane
Year: 2009 PMID: 19562087 PMCID: PMC2701678 DOI: 10.3389/neuro.07.013.2009
Source DB: PubMed Journal: Front Integr Neurosci ISSN: 1662-5145
Figure 3Modulation of KA-induced slow oscillations in firing by CB1 receptors. (A) Representative integrated firing rate histograms (bin width 10 s) illustrating KA-induced macro-burst firing pattern (periodicity ∼200 s). Injection of HU210 abolished this slow oscillatory firing activity. (B) Pre-treatment with the CB1 antagonist rimonabant (SR) completely blocked the actions of HU210. Arrow heads indicate the time of HU210 (100 μg kg−1) or rimonabant (3 mg kg−1) injections during KA (10 mg kg−1). All doses i.p.
Figure 1Cannabinoids reverse kainate-induced epileptiform-like activity in the hippocampus. (A) Representative spike rasters for nine simultaneously recorded neurons showing activity during pre-drug basal firing (upper panel) and the induction of synchronous burst firing induced by kainate (KA; 10 mg kg−1; middle panel). HU210 (100 μg kg−1) reversed the KA-induced synchronous activity to that seen during basal activity. (B) Representative cross-correlation histogram (CCH) analyses (with auto-correlogram for neuron 1) for the same neurones shown in the raster displays above. CCHs again illustrate KA-induce synchronous activity and its reversal by HU210. CCH reference was neuron 1 (time 0); bin width 1 ms. All doses i.p.
Figure 2Incidence of mean burst rate (bursts per analysis epoch ± SEM) as a function of drug treatment. KA significantly increased the burst frequency from pre-drug basal activity and entrained the network to burst synchronously. Co-application of the CB1 receptor agonist HU210 (HU) significantly decreased burst rate and disrupted the synchronicity in firing induced by KA. When injected in the presence of the CB1 receptor antagonist rimonabant (SR), HU210 did not alter KA-induced synchronous bursting activity (**p < 0.01; ***p < 0.005 vs baseline and &&p < 0.01 vs KA-induced bursting).